These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 16842197)

  • 1. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
    Jain RK; Duda DG; Clark JW; Loeffler JS
    Nat Clin Pract Oncol; 2006 Jan; 3(1):24-40. PubMed ID: 16407877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis as targeted breast cancer therapy.
    Hayes DF; Miller K; Sledge G
    Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor and bevacitumab in breast cancer.
    Bando H
    Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy.
    Gatto B; Cavalli M
    Anticancer Agents Med Chem; 2006 Jul; 6(4):287-301. PubMed ID: 16842232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
    Murukesh N; Dive C; Jayson GC
    Br J Cancer; 2010 Jan; 102(1):8-18. PubMed ID: 20010945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic anti-VEGF antibodies.
    Lien S; Lowman HB
    Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.